AbbVie
Biopharmaceutical medicine creation
- B2B
- B2C
- Has physical offices
- Publicly traded
- Manufacturing
- Sales-led purchase
About AbbVie
Global biopharmaceutical company focused on creating impactful medicines for complex health issues in immunology, oncology, neuroscience, eye care, aesthetics, and other unmet needs
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,000+ employees
- Headquarters
- North Chicago, Illinois, United States
- Revenue
- $61.2BFY2025, publicly reported
- Website
- abbvie.com
- linkedin.com/company/abbvie
AbbVie competitors
Jobs at AbbVie
- Associate Director, Data & Analytics Lead
- Data Strategy Lead - Hybrid
- Clinical Director, Clinical Data and AI Convergence
- Manager, Business Systems - IT Warehousing Capabilities
- Brand Manager, IT
- Manager, Global EHS Compliance
- Associate Scientist, Data II
- Senior Director, Category Management and Procurement – API and Third Party Manufacturing
AbbVie in the news
- Better Dividend for Retirees: AbbVie vs. Merck
AbbVie and Merck offer attractive dividends, but AbbVie has new growing drugs to compensate for the expired Humira patent, while Merck faces a patent cliff with Keytruda.
- Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL
Genmab and AbbVie announced their drug epcoritamab combined with standard chemotherapy significantly improved progression-free survival in a Phase 3 trial for diffuse large B-cell lymphoma patients.
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab's new drug, Rina-S, showed better efficacy and safety than AbbVie's Elahere for ovarian cancer, leading analysts to predict higher sales for Rina-S despite a legal dispute.
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
AbbVie successfully navigated its patent cliff with new drugs, leading to revenue growth, while Bristol Myers Squibb, despite facing upcoming patent expirations, has higher net margins and a lower valuation.
- Is AbbVie (ABBV) Still Undervalued On FDA Approval And Fresh Pipeline Data?
AbbVie's stock shows strong growth and is considered undervalued by some, driven by new drug approvals and pipeline data, despite a high P/E ratio and future risks.
AbbVie at a glance
AbbVie is a B2B/B2C company in the Pharmaceutical Manufacturing industry, headquartered in North Chicago, Illinois, United States.
AbbVie has 10,000+ employees.
AbbVie's revenue is $61.2B (FY2025, publicly reported).
AbbVie is hiring: 8 recent open roles, including Associate Director, Data & Analytics Lead, Data Strategy Lead - Hybrid, Clinical Director, Clinical Data and AI Convergence.
Selling to companies like AbbVie?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies